VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISA 2022 | The impact of clonal features on the survival of patients with non-cardiac AL amyloidosis

Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, comments on the impact of clonal features on the diagnosis, overall survival (OS), and hematologic event-free survival (EFS) of patients with non-cardiac AL amyloidosis, and highlights the importance of using this information to guide treatment decisions. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Disclosures

Janssen

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter